Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: Derivation of a clinical algorithm

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Albrich, Werner C ^a   Dusemund, Frank ^a   Rüegger, Kristina ^a   Christ Crain, Mirjam ^b   Zimmerli, Werner ^a   Bregenzer, Thomas ^c   Irani, Sarosh ^c   Buergi, Ulrich ^c   Reutlinger, Barbara ^c   Mueller, Beat ^a   Schuetz, Philipp ^d  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Department of Internal Medicine ^*  (Switzerland)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROADRENOMEDULLIN; ADRENOMEDULLIN; DIAGNOSTIC AGENT; PROTEIN PRECURSOR;

ACCURACY; ADULT; ADVERSE OUTCOME; AGED; ALGORITHM; AMBULATORY CARE; ARTICLE; CLINICAL ASSESSMENT TOOL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT CARE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; RESPIRATORY TRACT INFECTION;

ADRENOMEDULLIN; AGED; AGED, 80 AND OVER; ALGORITHMS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; RESPIRATORY TRACT INFECTIONS;

EID: 79955517658     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-112     Document Type: Article

References (44)

1. File TM, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgraduate medicine 122(2):130-141.
2. Lim WS, Macfarlane JT, Boswell TC, Harrison TG, Rose D, Leinonen M, Saikku P. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001, 56(4):296-301. 10.1136/thorax.56.4.296, 1746017, 11254821.
3. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58(5):377-382. 10.1136/thorax.58.5.377, 1746657, 12728155.
4. Schuetz P, Koller M, Christ-Crain M, Steyerberg E, Stolz D, Muller C, Bucher HC, Bingisser R, Tamm M, Muller B. Predicting mortality with pneumonia severity scores: importance of model recalibration to local settings. Epidemiology and infection 2008, 136(12):1628-1637. 10.1017/S0950268808000435, 2870789, 18302806.
5. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. The New England journal of medicine 1997, 336(4):243-250. 10.1056/NEJM199701233360402, 8995086.
6. Chang CL, Sullivan GD, Karalus NC, Mills GD, McLachlan JD, Hancox RJ. Predicting Early Mortality in Acute Exacerbation of Chronic Obstructive Pulmonary Disease using the CURB65 score. Respirology 2010,
7. Howell MD, Donnino MW, Talmor D, Clardy P, Ngo L, Shapiro NI. Performance of severity of illness scoring systems in emergency department patients with infection. Acad Emerg Med 2007, 14(8):709-714. 10.1111/j.1553-2712.2007.tb01866.x, 17576773.
8. Christ-Crain M, Schuetz P, Muller B. Biomarkers in the management of pneumonia. Expert review of respiratory medicine 2008, 2(5):565-572. 10.1586/17476348.2.5.565, 20477291.
9. Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype?. Swiss Med Wkly 2009, 139(23-24):318-326.
10. Schuetz P, Christ-Crain M, Morgenthaler NG, Struck J, Bergmann A, Muller B. Circulating precursor levels of endothelin-1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium 2007, 14(6):345-351. 10.1080/10623320701678326, 2430170, 18080871.
11. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Muller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Critical care (London, England) 2005, 9(6):R816-824.
12. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004, 25(8):1369-1372. 10.1016/j.peptides.2004.06.019, 15350706.
13. Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconier C, Widmer I, Neidert S, Fricker T, Blum C, Schild U, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Critical care (London, England) 14(3):R106.
14. Huang DT, Angus DC, Kellum JA, Pugh NA, Weissfeld LA, Struck J, Delude RL, Rosengart MR, Yealy DM. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009, 136(3):823-831. 10.1378/chest.08-1981, 2818411, 19363212.
15. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S, Tamm M, Struck J, Bergmann A, Muller B. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Critical care (London, England) 2006, 10(3):R96..
16. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, Periat P, Bucher HC, Christ-Crain M. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Archives of internal medicine 2008, 168(18):2000-2007. discussion 2007-2008, 10.1001/archinte.168.18.2000, 18852401.
17. Linscheid P, Seboek D, Zulewski H, Keller U, Muller B. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology 2005, 146(6):2699-2708. 10.1210/en.2004-1424, 15761041.
18. Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, Ritz R. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Critical care medicine 2000, 28(4):977-983. 10.1097/00003246-200004000-00011, 10809269.
19. Becker KL, Nylen ES, White JC, Muller B, Snider RH. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. The Journal of clinical endocrinology and metabolism 2004, 89(4):1512-1525. 10.1210/jc.2002-021444, 15070906.
20. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302(10):1059-1066. 10.1001/jama.2009.1297, 19738090.
21. Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C, Widmer I, Neidert S, Blum CA, Schonenberger R, et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC health services research 2007, 7:102. 10.1186/1472-6963-7-102, 1947969, 17615073.
22. Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet 2003, 362(9389):1053-1061. 10.1016/S0140-6736(03)14416-9, 14522537.
23. Gonzales R, Sande MA. Uncomplicated acute bronchitis. Annals of internal medicine 2000, 133(12):981-991.
24. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. American journal of respiratory and critical care medicine 2001, 163(7):1730-1754.
25. Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJ. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005, 26(6):1138-1180. 10.1183/09031936.05.00055705, 16319346.
26. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clinical chemistry 2005, 51(10):1823-1829. 10.1373/clinchem.2005.051110, 16099941.
27. Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, Niederman MS, Torres A. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998, 158(4):1102-1108.
28. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995, 8(8):1398-1420. 10.1183/09031936.95.08081398, 7489808.
29. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-72.
30. Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, Jackson R, Schousboe M, Frampton C, Hutton S, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996, 51(10):1010-1016. 10.1136/thx.51.10.1010, 472650, 8977602.
31. Baehni C, Meier S, Spreiter P, Schild U, Regez K, Bossart R, Thomann R, Falconnier C, Christ-Crain M, De Geest S, et al. Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives. BMC pulmonary medicine 10:12.
32. Aujesky D, McCausland JB, Whittle J, Obrosky DS, Yealy DM, Fine MJ. Reasons why emergency department providers do not rely on the pneumonia severity index to determine the initial site of treatment for patients with pneumonia. Clin Infect Dis 2009, 49(10):e100-108. 10.1086/644741, 19842971.
33. Escalante CP, Weiser MA, Manzullo E, Benjamin R, Rivera E, Lam T, Ho V, Valdres R, Lee EL, Badrina N, et al. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 2004, 12(9):657-662.
34. Leff B, Burton L, Mader SL, Naughton B, Burl J, Inouye SK, Greenough WB, Guido S, Langston C, Frick KD, et al. Hospital at home: feasibility and outcomes of a program to provide hospital-level care at home for acutely ill older patients. Annals of internal medicine 2005, 143(11):798-808.
35. Coley CM, Li YH, Medsger AR, Marrie TJ, Fine MJ, Kapoor WN, Lave JR, Detsky AS, Weinstein MC, Singer DE. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Archives of internal medicine 1996, 156(14):1565-1571. 10.1001/archinte.156.14.1565, 8687265.
36. Shepperd S, Doll H, Angus RM, Clarke MJ, Iliffe S, Kalra L, Ricauda NA, Tibaldi V, Wilson AD. Avoiding hospital admission through provision of hospital care at home: a systematic review and meta-analysis of individual patient data. Cmaj 2009, 180(2):175-182. 2621299, 19153394.
37. Yap FH, Ho PL, Lam KF, Chan PK, Cheng YH, Peiris JS. Excess hospital admissions for pneumonia, chronic obstructive pulmonary disease, and heart failure during influenza seasons in Hong Kong. Journal of medical virology 2004, 73(4):617-623. 10.1002/jmv.20135, 15221909.
38. Aliyu ZY, Aliyu MH, McCormick K. Determinants for hospitalization in low-risk community acquired pneumonia. BMC infectious diseases 2003, 3:11. 10.1186/1471-2334-3-11, 165606, 12809564.
39. Marrie TJ, Huang JQ. Admission is not always necessary for patients with community-acquired pneumonia in risk classes IV and V diagnosed in the emergency room. Can Respir J 2007, 14(4):212-216. 2676365, 17551596.
40. Marrie TJ. The Pneumonia Severity Index score: time to move to a prospective study of patients with community-acquired pneumonia who are discharged from emergency departments to be managed on an ambulatory basis. Clin Infect Dis 2007, 44(1):50-52. 10.1086/509333, 17143814.
41. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. Jama 2000, 283(6):749-755. 10.1001/jama.283.6.749, 10683053.
42. Loeb M, Carusone SC, Goeree R, Walter SD, Brazil K, Krueger P, Simor A, Moss L, Marrie T. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial. Jama 2006, 295(21):2503-2510. 10.1001/jama.295.21.2503, 16757722.
43. Yealy DM, Auble TE, Stone RA, Lave JR, Meehan TP, Graff LG, Fine JM, Obrosky DS, Mor MK, Whittle J, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Annals of internal medicine 2005, 143(12):881-894.
44. Ross S. Composite outcomes in randomized clinical trials: arguments for and against. Am J Obstet Gynecol 2007, 196(2):119 e111-116.